Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

BIOLOGICAL: Sacituzumab tirumotecan
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: H1 Receptor Antagonist
DRUG: H2 Receptor Antagonist
DRUG: Acetaminophen (or equivalent)
DRUG: Dexamethasone (or equivalent)
DRUG: Steroid Mouthwash (dexamethasone or equivalent)

Sponsor

Merck Sharp & Dohme LLC